| Quarterly Financials | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
Revenue  | 0 | 0 | 286 | 165 | 119 | 144 | 160 |
| Expenses | 0 | 0 | 251 | 150 | 103 | 123 | 135 |
| EBITDA | 0 | 0 | 35 | 15 | 17 | 21 | 25 |
| Operating Profit % | 0 % | 0 % | 12 % | 9 % | 14 % | 14 % | 16 % |
| Depreciation | 0 | 0 | 3 | 2 | 1 | 2 | 2 |
| Interest | 0 | 0 | 14 | 8 | 7 | 8 | 11 |
| Profit Before Tax | 0 | 0 | 20 | 7 | 9 | 13 | 14 |
| Tax | 0 | 0 | 7 | 1 | 2 | 3 | 4 |
| Net Profit | 0 | 0 | 14 | 6 | 7 | 9 | 11 |
| EPS in ₹ | 0.00 | 0.00 | 29.09 | 12.71 | 14.33 | 19.98 | 22.19 |
Fredun Pharmaceuticals
Fredun Pharmaceuticals
2,420.00
+55.00
(2.33%)
Market Cap
1,334.12 Cr
PE Ratio
39.90
Volume
7,219.00
Day High - Low
2,465.00 - 2,341.00
52W High-Low
2,550.00 - 690.00
Key Fundamentals
Market Cap
1,334.12 Cr
EPS
42.53
PE Ratio
39.90
PB Ratio
5.09
Book Value
464.61
EBITDA
54.90
Dividend Yield
0.03 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
13.96
Debt to Equity
1.18
Actual
Company News
View All News
Fredun Pharmaceuticals unveils DAULCÉL, a premium wellness brand focused on cellular longevity, NAD+ science, and preventive healthcare in India's emerging wellness segment.
Fredun Pharmaceuticals announces the strategic launch of its premium Hormone Range Products brand, targeting longevity, hormone health, and human performance therapeutics.
Fredun Pharmaceuticals' Board of Directors met on May 15, 2026, to take note of the Monitoring Agency Report for the quarter ended March 31, 2026.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,880.30 | #1 4,51,146.95 | 41.23 | #1 54,729.00 | 9.71 | #1 10,980 | 16.07 | 62.59 | |
6,893.00 | 1,82,987.49 | 74.03 | 9,712.00 | 18.67 | 2,191 | -1.02 | 67.94 | |
4,429.20 | 1,49,904.25 | 66.40 | 11,539.40 | 6.99 | 1,911 | 26.24 | 58.71 | |
1,399.50 | 1,13,048.91 | 29.49 | 27,711.70 | -2.46 | 3,783 | -55.32 | 62.25 | |
1,321.90 | 1,10,331.46 | 26.78 | 33,593.30 | -0.44 | 3,998 | -86.05 | 56.14 | |
2,583.90 | 1,06,664.70 | 57.10 | 12,744.20 | 20.90 | 2,007 | 31.75 | 76.93 | |
1,040.85 | 1,04,733.86 | 20.40 | 23,511.00 | 18.55 | 4,615 | 7.82 | 70.41 | |
2,285.50 | 1,04,457.23 | #1 19.52 | 27,487.50 | 19.98 | 5,345 | #1 87.72 | 47.81 | |
1,517.50 | 88,136.65 | 25.21 | 32,345.60 | 9.43 | 3,484 | 7.59 | 72.25 | |
1,361.10 | 73,479.88 | 81.56 | 6,812.90 | #1 21.03 | 884 | 21.18 | 83.04 |
Growth Rate
Revenue Growth
-
Net Income Growth
-
Cash Flow Change
-116.70 %
ROE
-
ROCE
-
EBITDA Margin (Avg.)
-
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2025 |
| Total Assets | 487 |
| Fixed Assets | 53 |
| Current Assets | 428 |
| Capital Work in Progress | 0 |
| Investments | 2 |
| Other Assets | 433 |
| Total Equity & Liabilities | 487 |
| Current Liabilities | 328 |
| Non Current Liabilities | 18 |
| Total Equity | 141 |
| Reserve & Surplus | 136 |
| Share Capital | 5 |
Cash Flow
| Cash Flow | 2025 |
| Net Cash Flow | 4 |
| Investing Activities | -6 |
| Operating Activities | -29 |
| Financing Activities | 39 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Nov 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | May 2023 | Jun 2023 | Aug 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Apr 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Feb 2026 | Mar 2026 |
| Promoter | 52.04 % | 52.04 % | 52.04 % | 51.27 % | 51.27 % | 51.27 % | 51.04 % | 51.04 % | 50.34 % | 50.15 % | 49.62 % | 49.62 % | 49.33 % | 49.31 % | 49.16 % | 49.17 % | 48.92 % | 49.17 % | 48.93 % | 48.93 % | 48.93 % | 48.93 % | 48.93 % | 43.06 % | 43.06 % | 44.17 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.46 % | 1.06 % | 1.06 % |
| DIIs | 1.88 % | 1.88 % | 1.88 % | 1.69 % | 1.69 % | 1.69 % | 1.68 % | 1.68 % | 1.66 % | 1.65 % | 1.64 % | 1.64 % | 1.61 % | 1.60 % | 1.60 % | 1.60 % | 1.59 % | 1.60 % | 1.59 % | 1.59 % | 1.59 % | 1.59 % | 1.60 % | 3.48 % | 2.89 % | 2.83 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 41.01 % | 40.99 % | 40.77 % | 41.56 % | 41.90 % | 41.81 % | 42.02 % | 42.08 % | 42.48 % | 43.07 % | 43.64 % | 43.60 % | 43.48 % | 43.49 % | 43.67 % | 44.02 % | 43.94 % | 43.89 % | 44.21 % | 44.55 % | 44.50 % | 44.52 % | 43.74 % | 45.18 % | 45.63 % | 44.66 % |
| Others | 5.07 % | 5.09 % | 5.32 % | 5.47 % | 5.13 % | 5.23 % | 5.25 % | 5.19 % | 5.52 % | 5.13 % | 5.10 % | 5.14 % | 5.58 % | 5.60 % | 5.58 % | 5.22 % | 5.55 % | 5.35 % | 5.27 % | 4.93 % | 4.98 % | 4.96 % | 5.72 % | 7.83 % | 7.37 % | 7.28 % |
| No of Share Holders | 0 | 1,993 | 2,301 | 3,681 | 3,674 | 3,573 | 3,620 | 3,678 | 3,901 | 4,521 | 4,609 | 4,625 | 4,627 | 4,635 | 6,315 | 7,507 | 6,840 | 7,511 | 8,018 | 8,121 | 7,976 | 7,906 | 8,120 | 8,749 | 8,443 | 8,400 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.6 | 1 | 0.65 | 0.66 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.00 |
| Dividend Yield (%) | 0.42 | 0.24 | 0.56 | 0.14 | 0.08 | 0.09 | 0.1 | 0.1 | 0.04 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 25 May 2026 |  Quarterly Result Announcement | NA | 25 May 2026 | 2,390.55 | 2,365.00 |
| 18 Sept 2021 |  Dividend | ₹ 0.70 /share | 16 Sept 2021 | 415.70 | 454.45 |
| 22 Sept 2023 | Dividend | ₹ 0.70 /share | 22 Sept 2023 | 886.50 | 875.65 |
| 18 Jan 2024 |  Extraordinary General Meeting | NA | 18 Jan 2024 | 872.05 | 837.70 |
| 23 Sept 2024 | Dividend | ₹ 0.70 /share | 23 Sept 2024 | 981.65 | 767.60 |
| 30 Sept 2024 |  Annual General Meeting | NA | 30 Sept 2024 | 788.20 | 755.65 |
| 26 Oct 2024 | Quarterly Result Announcement | NA | 26 Oct 2024 | 774.70 | 726.85 |
| 04 Feb 2025 | Quarterly Result Announcement | NA | 04 Feb 2025 | 700.70 | 721.85 |
| 30 May 2025 | Quarterly Result Announcement | NA | 30 May 2025 | 724.55 | 771.00 |
| 30 Jul 2025 | Quarterly Result Announcement | NA | 30 Jul 2025 | 860.20 | 958.60 |
| 23 Sept 2025 | Dividend | ₹ 0.70 /share | 23 Sept 2025 | 771.65 | 1,216.75 |
| 30 Sept 2025 | Annual General Meeting | NA | 30 Sept 2025 | 1,211.90 | 1,309.50 |
| 22 Oct 2025 | Extraordinary General Meeting | NA | 22 Oct 2025 | 1,306.50 | 1,660.80 |
| 08 Nov 2025 | Quarterly Result Announcement | NA | 08 Nov 2025 | 1,723.30 | 1,551.30 |
| 09 Feb 2026 | Quarterly Result Announcement | NA | 09 Feb 2026 | 1,489.50 | 1,648.00 |
| 16 Feb 2026 | Extraordinary General Meeting | NA | 16 Feb 2026 | 1,495.45 | 1,818.05 |
Announcements
Announcement under Regulation 30 (LODR)-Press Release / Media Release
5 days ago
5 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release5 days ago
5 days agoAnnouncement under Regulation 30 (LODR)-Monitoring Agency Report5 days ago
5 days agoBoard Meeting Outcome for Outcome Of Board Meeting Dated 15.05.20265 days ago
5 days agoBoard Meeting Intimation for The Meeting To Be Held On Monday 25 May 2026.5 days ago
5 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 29, 2026
Apr 29, 2026Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 28, 2026
Apr 28, 2026Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Apr 15, 2026
Apr 15, 2026Disclosure Under Regulation 7(2) Of SEBI (Prohibition Of Insider Trading) Regulations 2015.Apr 13, 2026
Apr 13, 2026Announcement under Regulation 30 (LODR)-AllotmentApr 09, 2026
Apr 09, 2026Announcement under Regulation 30 (LODR)-Conversion of SecuritiesApr 09, 2026
Apr 09, 2026Board Meeting Outcome for Outcome Of Board Meeting Dated 09Th April 2026Apr 09, 2026
Apr 09, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 06, 2026
Apr 06, 2026Closure of Trading WindowMar 26, 2026
Mar 26, 2026Disclosure Under Regulation 7(2) Of SEBI (Prohibition Of Insider Trading) Regulations 2015.Mar 26, 2026
Mar 26, 2026Announcement under Regulation 30 (LODR)-Meeting UpdatesMar 25, 2026
Mar 25, 2026Announcement under Regulation 30 (LODR)-AllotmentMar 25, 2026
Mar 25, 2026Announcement under Regulation 30 (LODR)-Conversion of SecuritiesMar 25, 2026
Mar 25, 2026Board Meeting Outcome for Outcome Of Board Meeting Dated 25Th March 2026Mar 25, 2026
Mar 25, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 21, 2026
Mar 21, 2026Announcement under Regulation 30 (LODR)-Meeting UpdatesMar 16, 2026
Mar 16, 2026Analyst/Institutional Investors Meeting Held On Wednesday 11Th March 2026 Organised By Arihant Capital - Bharat Connect Conference Rising Star 2026.Mar 12, 2026
Mar 12, 2026Intimation Of Schedule Of Bharat Connect Conference Under The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.Mar 05, 2026
Mar 05, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 25, 2026
Feb 25, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 25, 2026
Feb 25, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 17, 2026
Feb 17, 2026Announcement under Regulation 30 (LODR)-Change in ManagementFeb 16, 2026
Feb 16, 2026Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportFeb 16, 2026
Feb 16, 2026Shareholder Meeting / Postal Ballot-Outcome of EGMFeb 16, 2026
Feb 16, 2026Statement Of Deviation Or Variation For The Quarter Ended December 31 2025Feb 14, 2026
Feb 14, 2026Announcement under Regulation 30 (LODR)-Monitoring Agency ReportFeb 14, 2026
Feb 14, 2026Board Meeting Outcome for Outcome Of The Board Meeting Held On Saturday February 14 2026 At 05:00 P.M Through Video Conferencing (VC)Feb 14, 2026
Feb 14, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 12, 2026
Feb 12, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 11, 2026
Feb 11, 2026Revised OutcomeFeb 09, 2026
Feb 09, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 09, 2026
Feb 09, 2026Un-Audited Financial Results Of The Company For The Quarter And Nine Months Ended 31St December 2025Feb 09, 2026
Feb 09, 2026Board Meeting Outcome for Un-Audited Financial Results Of The Company For The Quarter And Nine Months Ended 31St December 2025Feb 09, 2026
Feb 09, 2026Board Meeting Intimation for Prior Intimation For The Board Meeting Of The Company To Be Held On Monday 09Th February 2026Jan 30, 2026
Jan 30, 2026Notice Of Book Closure For The Purpose Of Extra Ordinary General Meeting (EGM)Jan 20, 2026
Jan 20, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 20, 2026
Jan 20, 2026 Notice Convening Extra-Ordinary General Meeting (EGM) Of Fredun Pharmaceuticals LimitedJan 19, 2026
Jan 19, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 15, 2026
Jan 15, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 13, 2026
Jan 13, 2026Closure of Trading WindowDec 31, 2025
Dec 31, 2025Announcement under Regulation 30 (LODR)-AllotmentDec 29, 2025
Dec 29, 2025Announcement under Regulation 30 (LODR)-AllotmentDec 29, 2025
Dec 29, 2025Corrigendum Through General Announcement Regarding Disclosure Of Pre-Preferential Shareholding Of Proposed Allottees Ultimate Beneficial Owners (Ubos) Revised Issue Size Of Proposed Preferential Allotment Revised List Of Allottees And Bifurcation And BrieDec 18, 2025
Dec 18, 2025Corrigendum Through General Announcement Regarding Disclosure Of Pre-Preferential Shareholding Of Proposed Allottees Ultimate Beneficial Owners (Ubos) Revised Issue Size Of Proposed Preferential Allotment Revised List Of Allottees And Bifurcation And BrieDec 18, 2025
Dec 18, 2025Intimation Of Outcome Of Analysts/Investors Meeting Under The SEBI (Listing Obligations And Disclosures Requirements) Regulation 2015Dec 17, 2025
Dec 17, 2025Technical Indicators
RSI(14)
Neutral 60.94
ATR(14)
Less Volatile 153.51
STOCH(9,6)
Neutral 54.48
STOCH RSI(14)
Oversold 3.83
MACD(12,26)
Bearish -18.81
ADX(14)
Strong Trend 38.18
UO(9)
Bearish 52.22
ROC(12)
Uptrend And Accelerating 6.01
WillR(14)
Neutral -34.97
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
